Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements

American Journal of the Medical Sciences

Volumn 332, Issue 2, 2006, Pages 73-78

  Goodwin, Kayla D ^a   Ahokas, Robert A ^a   Bhattacharya, Syamal K ^a   Sun, Yao ^a   Gerling, Ivan C ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CALCITRIOL; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; HYDROGEN PEROXIDE; MAGNESIUM; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIET SUPPLEMENTATION; HYPERALDOSTERONISM; MALE; NONHUMAN; OXIDATIVE STRESS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PERIPHERAL BLOOD MONONUCLEAR CELL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY HYPERPARATHYROIDISM; STATISTICAL ANALYSIS;

ALDOSTERONE; ANIMALS; CALCITRIOL; CALCIUM; CYTOPLASM; DIETARY SUPPLEMENTS; HEART FAILURE, CONGESTIVE; HUMANS; HYDROGEN PEROXIDE; HYPERALDOSTERONISM; HYPERPARATHYROIDISM, SECONDARY; LEUKOCYTES, MONONUCLEAR; MAGNESIUM; MALE; OXIDATIVE STRESS; PARATHYROID HORMONE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33745612243     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200608000-00004     Document Type: Article

References (57)

1. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
2. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
3. Rousseau MF, Gurné O, van Eyll C, et al. Effects of benazeprilat on left ventricular systolic and diastolic function and neurohormonal status in patients with ischemic heart disease. Circulation 1990;81:III123-III29.
4. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
5. Villarreal D, Freeman RH, Johnson RA. Neurohormonal modulators and sodium balance in experimental heart failure. Am J Physiol 1993;264:H1187-H93.
6. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18.
7. Cesselli D, Jakoniuk I, Barlucchi L, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001;89:279-86.
8. Miyamoto M, Kishimoto C, Shioji K, et al. Cutaneous arteriolar thioredoxin expression in patients with heart failure. Circ J 2003;67:116-8.
9. Tsutsui H, Ide T, Hayashidani S, et al. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation 2001;104:134-6.
10. Ahokas RA, Warrington KJ, Gerling IC, et al. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res 2003;93:e124-e35.
11. 2 in peripheral blood mononuclear cells. Circulation 2005;111:51-7.
12. Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes the proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 2003;285:H813-H21.
13. Aukrust P, Ueland T, Müller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-43.
14. Damås JK, Gullestad L, Aass H, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001;38:187-93.
15. Damås JK, Gullestad L, Ueland T, et al. CXC-chemokines, a new group of cytokines in congestive heart failure - possible role of platelets and monocytes. Cardiovasc Res 2000;45:428-36.
16. Yndestad A, Damås JK, Eiken HG, et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res 2002;54:175-82.
17. Yndestad A, Holm AM, Müller F, et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003;60:141-6.
18. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002;161:1773-81.
19. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34.
20. Anker SD, Clark AL, Teixeira MM, et al. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol 1999;83:612-5.
21. Lee AH, Mull RL, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994;96:35-41.
22. Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997;103:197-207.
23. Weber KT. The proinflammatory heart failure phenotype: a case of integrative physiology. Am J Med Sci 2005;330:219-26.
24. Schmid C, Kiowski W. Hyperparathyroidism in congestive heart failure. Am J Med 1998;104:508-9.
25. Khouzam RN, Dishmon DA, Farah V, et al. Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci 2006;331:30-4.
26. LaGuardia SP, Dockery BK, Bhattacharya SK, et al. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with heart failure. Am J Med Sci 2006 (in press).
27. Chhokar VS, Sun Y, Bhattacharya SK, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2004;287:H2023-H26.
28. Chhokar VS, Sun Y, Bhattacharya SK, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005;111:871-8.
29. Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol Metab 1962;22:1187-92.
30. Rastegar A, Agus Z, Connor TB, et al. Renal handling of calcium and phosphate during mineralocorticoid "escape" in man. Kidney Int 1972;2:279-86.
31. Cappuccio FP, Markandu ND, MacGregor GA. Renal handling of calcium and phosphate during mineralocorticoid administration in normal subjects. Nephron 1988;48:280-3.
32. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med 1985;78:385-90.
33. Rossi E, Sani C, Perazzoli F, et al. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens 1995;8:884-93.
34. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 1994;14:219-31.
35. Smogorzewski M, Massry SG. Uremic cardiomyopathy: role of parathyroid hormone. Kidney Int Suppl 1997;62:S12-S14.
36. Vidal A, Sun Y, Bhattacharya SK, et al. The calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol 2006;290:H286-H94.
37. Zemel MB, Kraniak J, Standley PR, et al. Erythrocyte cation metabolism in salt-sensitive hypertensive blacks as affected by dietary sodium and calcium. Am J Hypertens 1988;1:386-92.
38. Haller H, Thiede M, Lenz T, et al. Intracellular free calcium and ionized plasma calcium during mineralocorticoid-induced blood pressure increase in man. J Hypertens Suppl 1985;3:S41-S43.
39. Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 2002;3:1129-34.
40. Zikos D, Langman C, Gafter U, et al. Chronic DOCA treatment increases Ca absorption: role of hypercalciuria and vitamin D. Am J Physiol 1986;251:E279-E84.
41. Breslau NA, McGuire JL, Zerwekh JE, et al. The role of dietary sodium on renal excretion and intestinal absorption of calcium and on vitamin D metabolism. J Clin Endocrinol Metab 1982;55:369-73.
42. Fiebeler A, Luft FC. The mineralocorticoid receptor and oxidative stress. Heart Fail Rev 2005;10:47-52.
43. Fiebeler A, Schmidt F, Müller DN, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-κB activation in angiotensin II-induced cardiac injury. Hypertension 2001;37:787-93.
44. A-NADPH oxidase pathway in low-renin hypertension. Circulation 2003;107:1053-8.
45. Beswick RA, Zhang H, Marable D, et al. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001;37:781-6.
46. Park YM, Park MY, Suh YL, et al. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun 2004;313:812-7.
47. Iglarz M, Touyz RM, Viel EC, et al. Involvement of oxidative stress in the profibrotic action of aldosterone: interaction with the renin-angiotensin system. Am J Hypertens 2004;17:597-603.
48. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001;50:3-11.
49. Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504-10.
50. Pu Q, Neves MF, Virdis A, et al. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003;42:49-55.
51. Callera GE, Touyz RM, Teixeira SA, et al. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 2003;42:811-7.
52. Bhattacharya SK, Crawford AJ, Thakar JH, et al. Pathogenetic roles of intracellular calcium and magnesium in membrane-mediated progressive muscle degeneration in Duchenne muscular dystrophy. In: Fiskum G, editor. Cell Calcium Metabolism: Physiology, Biochemistry, Pharmacology, and Clinical Implications. New York: Plenum Press; 1989, p. 513-25.
53. Burniston JG, Saini A, Tan LB, et al. Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. J Mol Cell Cardiol 2005;39:395-99.
54. Mall G, Huther W, Schneider J, et al. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990;5:39-44.
55. Amann K, Ritz E, Wiest G, et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994;4:1814-19.
56. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
57. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.